The Thermo Fisher Scientific story
What drives Thermo Fisher Scientific, what its price assumes and what could change the story, written from its own filings.
- Demand is strengthening. Revenue in the quarter to September 2026 grew 9% to $12.14 billion, including 6% organic growth.
- Services carry more weight. Laboratory Products and Biopharma Services generated 56.5% of consolidated revenue before eliminations in the quarter to September 2026, with Clario adding clinical trial data capabilities.
- Cash has competing uses. Free cash flow of $4,618 million in the nine months to September 2026 accompanied acquisition spending of $8,877 million and repurchases of $4,000 million.
